Background/Aims: The present study prospectively examined whether or not a partial response at week 4 predicts subsequent response at week 8 during lamotrigine augmentation therapy in 51 (16 males and 35 females) inpatients with treatment-resistant depressive disorder using an open-study design. Methods: The subjects were 51 depressed patients who had already shown insufficient response to at least 3 psychotropics including antidepressants, mood stabilizers, and atypical antipsychotics. The diagnoses were major depressive disorder (n = 19), bipolar I disorder (n = 9), and bipolar II disorder (n = 23). The final doses of lamotrigine were 100 mg/day for 29 subjects who were not taking valproate and 75 mg/day for 22 subjects taking valproate. Depressive symptoms were evaluated by the Montgomery-Åsberg Depression Rating Scale (MADRS) before the start of lamotrigine and then at week 4, and finally after the 8th week of treatment. Results: A significant linear relationship was found between percent improvements in MADRS scores at weeks 4 and 8 (r = 0.492, y = 0.438x + 30.223, R2 = 0.226, p < 0.001). The receiver operating characteristics analysis indicated that a percent improvement of 16% or greater at week 4 was significantly (p < 0.01) predictive of response (50% or more reduction in the MADRS score). The patients were significantly divided by the cut-off point into the responders and the nonresponders (18/26 vs. 1/25, p < 0.001). Conclusion: The present study suggests that a partial response at week 4 can predict subsequent outcome at week 8 during lamotrigine augmentation therapy in patients with treatment-resistant depressive disorder, and that the absence of a partial improvement at week 4 is highly predictive of nonresponse.

Keywords:
Partial response, Lamotrigine, Augmentation therapy, Treatment-resistant depressive disorder, Response prediction
1.
Geddes JR, Calabrese JR, Goodwin GM: Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials. Br J Psychiatry 2009; 194: 4–9.
2.
Solmi M, Veronese N, Zaninotto L, van der Loos MLM, Gao K, Schaffer A, Reis C, Normann C, Anghelescu IG, Correl CU: Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectr 2016; 21: 403–418.
3.
Ivković M, Damjanović A, Jovanović A, Cvetić T, Jašović-Gašić M: Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability. Psychiatr Danub 2009; 21: 187–193.
4.
Kagawa S, Nemoto K, Suzuki T, Nagai G, Nakamura A, Mihara K, Kondo T: Lamotrigine augmentation for the treatment-resistant mood disorder. Clin Neuropsychopharmacol Ther 2010; 1: 35–42.
5.
Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, Thompson PM, Shelton RC: A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry 2011; 72: 1405–1412.
6.
Kagawa S, Mihara K, Nakamura A, Nemoto K, Suzuki T, Nagai G, Kondo T: Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder. Ther Drug Monit 2014; 36: 730–733.
7.
Nakamura A, Mihara K, Nagai G, Kagawa S, Suzuki T, Nemoto K, Kondo T: Prediction of an optimal dose of lamotrigine for augmentation therapy in treatment-resistant depressive disorder from plasma concentration at week 2. Ther Drug Monit 2016; 38: 379–382.
8.
Lamictal® (lamotrigine) (highlights of prescribing information). Research Triangle Park, GlaxoSmithKline, 2016.
9.
Szegedi A, Jansen WT, van Willigenburg APP, van der Meulen E, Stassen HH, Thase ME: Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6,562 patients. J Clin Psychiatry 2009; 70: 344–353.
10.
Kemp DE, Ganocy SJ, Brecher M, Carlson BX, Edwards S, Eudicone JM, Evoniuk G, Jansen W, Leon AC, Minkwitz M, Pikalov A, Stassen HH, Szegedi A, Tohen M, van Willigenburg APP, Calabrese JR: Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3,369 subjects with bipolar I or II depression. J Affect Disord 2011; 130: 171–179.
11.
Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, Monaghan ET, Leadbetter RA: Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008; 10: 323–333.
12.
Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD; for the Lamictal 602 study group: A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79–88.
13.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, Text Revision. Washington, American Psychiatric Association, 2000.
14.
Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389.
15.
Thase ME, Rush AJ: Treatment-resistant depression; in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 2005, pp 1081–1097.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.